Cooler News: Walk-In Freezer Innovations are Defying the Laws of Thermodynamics

 

The first modern freezer hit homes in the early 1900s. Since then, modern refrigeration and freezers have come a long way; the laws of thermodynamics, though, haven’t changed. The way in which people treat and manage their walk-in freezers often incurs more costs for a company, whether that’s in maintenance or energy costs, and it all ties back to thermodynamics. Research by scientists like today’s guest, though, KPS Global’s Technical Fellow James Costanza, has made modern industrial walk-in freezers more efficient, longer-lasting, and environmentally friendly.

Costanza first breaks down how energy flows, from a higher level to lower level of energy. He elaborates on the biggest thermodynamic challenges facing the construction of walk-in freezers today: conductance, convection, condensation, and radiation. These challenges have faced scientists and engineers since refrigeration began evolving over 200 years ago.

“Historically the cold storage industry…has been relatively stagnant in significant innovations,” Costanza said. But he continues to explain how KPSG has married elements of strength, such as insulated panels, and elements of thermal properties to craft a single product (a “FUSIONFRAME system”) that is a significant improvement in the industry, for the customer and the environment.

Perhaps the biggest challenge to Costanza and his team is condensation. He said condensation is “…the single largest issue related to storage of cold storage envelopes.“ So how do engineers battle the ongoing threat of condensation build-up, material deterioration, and mold growth? He explains the design in laymen’s terms, emphasizing how important it is to minimize condensation, particularly in food preparation spaces. The engineering group and manufacturing group at KPSG has pulled off a true feat of science in their innovative new design of walk-in freezers.

Find out more about how KPSG developed the software and is playing a focused role in patient care by listening to the podcast.

Follow us on social media for the latest updates in B2B!

Twitter – @EnergyMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More